Inflammatory musculoskeletal diseases are common, painful and disabling. Rheumatoid arthritis (RA) has a global prevalence of 1% and costs the UK £9 billion per year. Sjögren’s syndrome (SjS) is associated with poor quality-of-life, lymphoma risk and similar per-patient costs to RA. Through patient engagement with our Birmingham Rheumatology Research Patient Partnership we have refined our previous BRC’s translational arthritis strategy to deliver a programme that will improve clinical outcomes across the age spectrum and throughout the life-course of inflammatory arthritis and SjS.
Professor Karim Raza
Professor Andrew Filer